The New York Stem Cell Foundation Research Institute researchers have reported their study on clinical-grade cells in the Stem Cell Research and Therapy journal. This valuable progress can help treat bone diseases or other injuries within a limited time span. In the present study, two different growth media were used to support the growth of the mesenchymal progenitor (MP) cells arising from the stem cells in a clinical environment following Good Manufacturing Practice (GMP) practices.
The cellular therapies are the major focus of the university as there are millions of them in need of it. For standing up to the therapeutic market demands the produced cells have to be of high quality and clinically safe for further use. The major similarity is that these cells are exactly alike the mesenchymal stem cells (MSCs). The MSCs are the vital cells as they can form cartilage cells, fat cells, muscle cells, and bone cells or even alter the functions of various other cells. Generally, they are the target for cell therapies in which hale and hearty cells are launched into the body to care for diseases or rebuild tissues and organs.
According to Ralph Lauren, the MP cells are basically the copies of iPSCs, however not in a growth medium devoid of animal-derived compounds. One of the most fascinating features is that the MP cells cultivated in GMP-compliant media had the same functional and biological properties as the ones grown in research-grade media consisting of the animal products. All these studies can help the researchers plan for further analysis of these cells outside the lab or even in the clinics. The researchers have even added fetal bovine serum to the medium for MP cells growth enhancement. The MP cells grown in the animal-derived compounds absent growth medium were referred to as xeno-free and these cells were given mercantile high-performance GMP media such as AllegroTM Unison Medium and human platelet lysates for accelerating their development. The cells from both the media showed different properties, thus proving positive for further application in cellular therapies. Researchers from the Salk Institute along with colleagues from Stanford University and Baylor College of Medicine have persuaded certain cells to grow into nerve cells using a unique method such that molecules match the signature neurons in the brain and help treat some neurological diseases.